TY - JOUR
T1 - Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma
T2 - Selective occurrence after lenalidomide
AU - Montefusco, Vittorio
AU - Galli, Monica
AU - Spina, Francesco
AU - Stefanoni, Paola
AU - Mussetti, Alberto
AU - Perrone, Giulia
AU - De Philippis, Chiara
AU - Dalto, Serena
AU - Maura, Francesco
AU - Bonini, Chiara
AU - Rezzonico, Francesca
AU - Pennisi, Martina
AU - Roncari, Luisa
AU - Soldarini, Martina
AU - Dodero, Anna
AU - Farina, Lucia
AU - Cocito, Federica
AU - Caprioli, Chiara
AU - Corradini, Paolo
PY - 2014
Y1 - 2014
N2 - Immunomodulatory drugs (IMiDs) may favor autoimmune disease (AD) occurrence. We conducted a retrospective study to evaluate AD occurrence among IMiD-treated patients with myeloma. Patients were grouped into three classes depending on the type of IMiD engaged. The first group included patients treated with thalidomide (Thal) (n = 474), the second group with lenalidomide (Len) (n = 140) and patients in the third group were first treated with Thal followed by Len (Thal-Len) (n = 94). Absolute risk of AD was 0.4% for patients treated with Thal, 4.3% for Len and 1.1% for Thal-Len. ADs manifested prevalently as autoimmune cytopenias (55%), although we observed one vasculitis, one optic neuritis, one Graves' disease and one polymyositis. ADs occurred preferentially in the first months of IMiD treatment. A previous autologous transplant was shown to be a significant risk factor. All ADs were managed with IMiD discontinuation and steroids, resolving in a few weeks, except for Graves' disease and polymyositis.
AB - Immunomodulatory drugs (IMiDs) may favor autoimmune disease (AD) occurrence. We conducted a retrospective study to evaluate AD occurrence among IMiD-treated patients with myeloma. Patients were grouped into three classes depending on the type of IMiD engaged. The first group included patients treated with thalidomide (Thal) (n = 474), the second group with lenalidomide (Len) (n = 140) and patients in the third group were first treated with Thal followed by Len (Thal-Len) (n = 94). Absolute risk of AD was 0.4% for patients treated with Thal, 4.3% for Len and 1.1% for Thal-Len. ADs manifested prevalently as autoimmune cytopenias (55%), although we observed one vasculitis, one optic neuritis, one Graves' disease and one polymyositis. ADs occurred preferentially in the first months of IMiD treatment. A previous autologous transplant was shown to be a significant risk factor. All ADs were managed with IMiD discontinuation and steroids, resolving in a few weeks, except for Graves' disease and polymyositis.
KW - Autoimmune diseases
KW - Lenalidomide
KW - Multiple myeloma
KW - Thalidomide
UR - http://www.scopus.com/inward/record.url?scp=84906052553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906052553&partnerID=8YFLogxK
U2 - 10.3109/10428194.2014.914203
DO - 10.3109/10428194.2014.914203
M3 - Article
C2 - 24730540
AN - SCOPUS:84906052553
VL - 55
SP - 2032
EP - 2037
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 9
ER -